PURPOSE: To investigate the change of breast density with quantitative magnetic resonance (MR) imaging in the contralateral normal breast of patients receiving neoadjuvant chemotherapy. MATERIALS AND METHODS: This study was approved by the institutional review board and was HIPAA compliant. Informed consent was obtained. Fifty-four patients with breast cancer (mean age, 47 years; age range, 30-74 years) treated with NAC protocol and enrolled in a breast MR imaging research study were studied. The density in the contralateral normal breast was analyzed by using an MR imaging-based segmentation method. The effect of chemotherapy on the change of density following the doxorubicin and cyclophosphamide (AC) and the AC and taxane regimen was evaluated. The dependence on age was investigated by using a multivariate regression model. RESULTS: In patients who underwent both AC and taxane follow-up, the mean percentage of change from the individual's baseline density was -10% (95% confidence interval: -12.8%, -7.2%) after AC and -12.7% (95% confidence interval: -16%, -9.4%) after AC and taxane. In patients who underwent both follow-up studies after one to two and four cycles of AC, the mean percentage of change was -9.4% (95% confidence interval: -13.5%, -5.3%) after one to two cycles of AC and -14.7% (95% confidence interval: -20.6%, -8.7%) after four cycles of AC. The percentage reduction of density was significantly dependent on age. Patients younger than 40 years had a greater reduction after chemotherapy than patients older than 55 years (P = .01). CONCLUSION: By using three-dimensional MR imaging, patients receiving chemotherapy showed reduction of breast density, and the effects were significant after initial treatment with one to two cycles of the AC regimen. RSNA, 2010
PURPOSE: To investigate the change of breast density with quantitative magnetic resonance (MR) imaging in the contralateral normal breast of patients receiving neoadjuvant chemotherapy. MATERIALS AND METHODS: This study was approved by the institutional review board and was HIPAA compliant. Informed consent was obtained. Fifty-four patients with breast cancer (mean age, 47 years; age range, 30-74 years) treated with NAC protocol and enrolled in a breast MR imaging research study were studied. The density in the contralateral normal breast was analyzed by using an MR imaging-based segmentation method. The effect of chemotherapy on the change of density following the doxorubicin and cyclophosphamide (AC) and the AC and taxane regimen was evaluated. The dependence on age was investigated by using a multivariate regression model. RESULTS: In patients who underwent both AC and taxane follow-up, the mean percentage of change from the individual's baseline density was -10% (95% confidence interval: -12.8%, -7.2%) after AC and -12.7% (95% confidence interval: -16%, -9.4%) after AC and taxane. In patients who underwent both follow-up studies after one to two and four cycles of AC, the mean percentage of change was -9.4% (95% confidence interval: -13.5%, -5.3%) after one to two cycles of AC and -14.7% (95% confidence interval: -20.6%, -8.7%) after four cycles of AC. The percentage reduction of density was significantly dependent on age. Patients younger than 40 years had a greater reduction after chemotherapy than patients older than 55 years (P = .01). CONCLUSION: By using three-dimensional MR imaging, patients receiving chemotherapy showed reduction of breast density, and the effects were significant after initial treatment with one to two cycles of the AC regimen. RSNA, 2010
Authors: H M Kuerer; L A Newman; T L Smith; F C Ames; K K Hunt; K Dhingra; R L Theriault; G Singh; S M Binkley; N Sneige; T A Buchholz; M I Ross; M D McNeese; A U Buzdar; G N Hortobagyi; S E Singletary Journal: J Clin Oncol Date: 1999-02 Impact factor: 44.544
Authors: G Bonadonna; P Valagussa; C Brambilla; L Ferrari; A Moliterni; M Terenziani; M Zambetti Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: B Fisher; J Bryant; N Wolmark; E Mamounas; A Brown; E R Fisher; D L Wickerham; M Begovic; A DeCillis; A Robidoux; R G Margolese; A B Cruz; J L Hoehn; A W Lees; N V Dimitrov; H D Bear Journal: J Clin Oncol Date: 1998-08 Impact factor: 44.544
Authors: E White; P Velentgas; M T Mandelson; C D Lehman; J G Elmore; P Porter; Y Yasui; S H Taplin Journal: J Natl Cancer Inst Date: 1998-06-17 Impact factor: 13.506
Authors: Daniel H-E Chang; Jeon-Hor Chen; Muqing Lin; Shadfar Bahri; Hon J Yu; Rita S Mehta; Ke Nie; David J B Hsiang; Orhan Nalcioglu; Min-Ying Su Journal: Med Phys Date: 2011-11 Impact factor: 4.071
Authors: C Cullinane; A O Brien; A Shrestha; E O Hanlon; J Walshe; J Geraghty; D Evoy; D McCartan; E McDermott; R Prichard Journal: Breast Cancer Res Treat Date: 2022-05-23 Impact factor: 4.624
Authors: Thomas D O'Sullivan; Anaïs Leproux; Jeon-Hor Chen; Shadfar Bahri; Alex Matlock; Darren Roblyer; Christine E McLaren; Wen-Pin Chen; Albert E Cerussi; Min-Ying Su; Bruce J Tromberg Journal: Breast Cancer Res Date: 2013-02-22 Impact factor: 6.466
Authors: Jingmei Li; Kamila Czene; Hiltrud Brauch; Werner Schroth; Pilar Saladores; Yi Li; Keith Humphreys; Per Hall Journal: Breast Cancer Res Date: 2013 Impact factor: 6.466